CAMBRIDGE, Mass., Oct. 03, 2017 -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, will present at the following upcoming healthcare conferences in October:
Tuesday, October 10, 2017
Chardan Gene Therapy Conference
Who: Tom Barnes, Ph.D., Senior Vice President, Innovation Sciences & eXtellia
Location: New York, New York
Presentation Time: 2:45 pm EDT
Thursday, October 12, 2017
Jefferies Gene Therapy and Editing Summit
Who: Nessan Bermingham, Ph.D., President, Chief Executive Officer and Founder
Location: New York, New York
Presentation Time: 1:40 pm EDT
A live webcast of Intellia’s presentations will be accessible through the Events and Presentations page of the Investor Relations section of the company’s website at www.intelliatx.com. To access the webcasts, please log on to the Intellia website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Intellia’s website for 14 days following each conference.
About Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. Our combination of deep scientific, technical and clinical development experience, along with our leading intellectual property portfolio, puts us in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com; Follow us on Twitter @intelliatweets.
Intellia Contacts:
Media Contact:
Jennifer Mound Smoter
Senior Vice President, External Affairs
& Communications
+1 857-706-1071
[email protected]
Investor Contact:
Lindsey Trickett
Vice President, Investor Relations
+1 857-285-6211
[email protected]


FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Instagram Outage Disrupts Thousands of U.S. Users
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 



